NASDAQ:KRSA Cyclerion Therapeutics (KRSA) Stock Price, News & Analysis $31.74 +0.08 (+0.25%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsNews and TrendsOwnershipSEC Filings About Cyclerion Therapeutics Stock (NASDAQ:KRSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cyclerion Therapeutics alerts:Sign Up Key Stats Today's Range$30.78▼$32.7050-Day Range N/A52-Week Range$7.19▼$59.36Volume57,483 shsAverage Volume287,964 shsMarket Capitalization$21.27 millionP/E RatioN/ADividend YieldN/APrice Target$53.00Consensus RatingModerate Buy Company Overview Cyclerion Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function. Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease. The company was founded in 2019 as a spinout from Ironwood Pharmaceuticals and was headquartered in Cambridge, Massachusetts. Peter Hecht, Ph.D., served as its chief executive officer during a significant portion of its operations. Public information identifies Cyclerion’s historical Nasdaq trading symbol as CYCN rather than KRSA, and the company’s corporate status and operations may have changed since its period as an independent biotechnology business.AI Generated. May Contain Errors. Read More Cyclerion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreKRSA MarketRank™: 2.93680052666 of 5 starsCyclerion Therapeutics scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCyclerion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCyclerion Therapeutics has a consensus price target of $53.00, representing about 67.7% upside from its current price of $31.60.Amount of Analyst CoverageCyclerion Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cyclerion Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cyclerion Therapeutics are expected to decrease in the coming year, from ($2.11) to ($3.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclerion Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclerion Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cyclerion Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.63% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently increased by 160.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclerion Therapeutics does not currently pay a dividend.Dividend GrowthCyclerion Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.21 News SentimentCyclerion Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cyclerion Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for KRSA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cyclerion Therapeutics' insider trading history. Receive KRSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRSA Stock News HeadlinesComparing Cyclerion Therapeutics (NASDAQ:CYCN) and Redhill Biopharma (NASDAQ:RDHL)October 8, 2026 | americanbankingnews.comCervoMed (NASDAQ:CRVO) versus Cyclerion Therapeutics (NASDAQ:CYCN) Head to Head AnalysisOctober 7, 2026 | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Wedbush Begins Coverage on Cyclerion Therapeutics (NASDAQ:KRSA)October 5, 2026 | americanbankingnews.comCyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Average Target Price of $56.00October 3, 2026 | americanbankingnews.comCyclerion Therapeutics (NASDAQ:KRSA) Upgraded at Wall Street ZenOctober 3, 2026 | americanbankingnews.comKorsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 MillionSeptember 8, 2026 | globenewswire.comCyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s PipelineApril 21, 2026 | finance.yahoo.comSee More Headlines KRSA Stock Analysis - Frequently Asked Questions How have KRSA shares performed this year? Cyclerion Therapeutics' stock was trading at $31.91 on September 11, 2026. Since then, KRSA shares have decreased by 1.0% and is now trading at $31.5980. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($5.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($120.40) by $115.08. When did Cyclerion Therapeutics' stock split? Cyclerion Therapeutics shares reverse split on the morning of Tuesday, May 16th 2023.The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Cyclerion Therapeutics? Shares of KRSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Energy Transfer (ET), Carnival (CCL) and OPKO Health (OPK). Company Calendar Last Earnings5/12/2026Today10/14/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KRSA's financial health is in the Green zone, according to TradeSmith. KRSA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:KRSA Previous SymbolNASDAQ:CYCN CIK1755237 Webwww.korsana.com Phone(617) 621-7722FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Cyclerion Therapeutics$53.00 High Price Target$70.00 Low Price Target$43.00 Potential Upside/Downside+67.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($11.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.53 million Net MarginsN/A Pretax Margin-353.00% Return on Equity-87.96% Return on Assets-74.86% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual Sales$2.07 million Price / Sales10.27 Cash FlowN/A Price / Cash FlowN/A Book Value$16.20 per share Price / Book1.96Miscellaneous Outstanding Shares670,000Free Float440,000Market Cap$21.27 million OptionableN/A Beta1.72 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:KRSA) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...Capital Trends | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
